AC Immune

LAUSANNE, Switzerland — September 23, 2026 AC Immune SA reported positive safety and immunogenicity results through Week 100 from...

LAUSANNE, Switzerland, August 20, 2026 AC Immune SA announced positive preliminary Phase 1 clinical data for ACI-19764, its wholly...

LAUSANNE, Switzerland, August 11, 2026 AC Immune SA announced that the U.S. Food and Drug Administration (FDA) has granted...

LAUSANNE, Switzerland, May 22, 2026 AC Immune announced new preliminary Phase 1 data showing that its investigational TDP-43 PET...

LAUSANNE, Switzerland, April 2026 AC Immune SA announced continued progress in its Phase 1b/2 ABATE clinical trial evaluating ACI-24,...

LAUSANNE, Switzerland — December 11, 2025 — AC Immune SA has released positive interim Phase 2 data for its...